With GLP-1 drugs shifting how people eat, Brand Finance studied the possible fallout for the largest food companies in the world.
Recap by typeshit. Post by Brand Finance on X.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
A sponsored-style explainer from telehealth provider Mochi Health on what the end of shortages means for compounded semaglutide and tirzepatide.
3:21
A short upload with no description, so the reasoning behind the claim isn't given. Worth a tap only if you follow the gray market retatrutide talk.
Loading…